Key result
In patients with coronary artery disease, nicorandil treatment was associated with a 35% reduction in all-cause death (HR 0.65) compared to no nicorandil treatment.
Why the study?
Does nicorandil reduce all-cause mortality in patients with coronary artery disease?
Observational (n=5,116)
Yes
Does nicorandil reduce all-cause mortality in patients with coronary artery disease?
Hazard Ratio: 0.65 (95% CI 0.51–0.84)
Absolute Event Rate: 15.23% vs 22.61%
p-value: p=0.0008
In a large observational cohort of Japanese patients with coronary artery disease, nicorandil therapy was associated with a significant 35% reduction in all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for mortality benefit in CAD; should not change practice pending randomized confirmation.
Horinaka et al. (2010) conducted an observational in Coronary artery disease (n=5,116). Nicorandil vs. No nicorandil treatment was evaluated on All-cause death (HR 0.65, 95% CI 0.51-0.84, p=0.0008). In patients with coronary artery disease, nicorandil treatment was associated with a 35% reduction in all-cause death (HR 0.65) compared to no nicorandil treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: